PACB vs. EDIT
Compare and contrast key facts about Pacific Biosciences of California, Inc. (PACB) and Editas Medicine, Inc. (EDIT).
Performance
PACB vs. EDIT - Performance Comparison
Loading graphics...
PACB vs. EDIT - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
PACB Pacific Biosciences of California, Inc. | -29.41% | 2.19% | -81.35% | 19.93% | -60.02% | -21.13% | 404.67% | -30.54% | 180.30% | -30.53% |
EDIT Editas Medicine, Inc. | 20.49% | 61.42% | -87.46% | 14.21% | -66.59% | -62.13% | 136.78% | 30.15% | -25.97% | 89.34% |
Fundamentals
PACB:
$398.52M
EDIT:
$219.20M
PACB:
-$1.82
EDIT:
-$1.82
PACB:
2.48
EDIT:
5.35
PACB:
74.50
EDIT:
8.03
PACB:
$160.01M
EDIT:
$40.52M
PACB:
$50.67M
EDIT:
$39.72M
PACB:
-$161.03M
EDIT:
$0.00
Returns By Period
In the year-to-date period, PACB achieves a -29.41% return, which is significantly lower than EDIT's 20.49% return. Over the past 10 years, PACB has outperformed EDIT with an annualized return of -17.78%, while EDIT has yielded a comparatively lower -23.69% annualized return.
PACB
- 1D
- 4.76%
- 1M
- -21.43%
- YTD
- -29.41%
- 6M
- 3.13%
- 1Y
- 11.86%
- 3Y*
- -51.51%
- 5Y*
- -47.73%
- 10Y*
- -17.78%
EDIT
- 1D
- 10.76%
- 1M
- 12.27%
- YTD
- 20.49%
- 6M
- -28.82%
- 1Y
- 112.93%
- 3Y*
- -30.16%
- 5Y*
- -43.48%
- 10Y*
- -23.69%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
PACB vs. EDIT — Risk / Return Rank
PACB
EDIT
PACB vs. EDIT - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Pacific Biosciences of California, Inc. (PACB) and Editas Medicine, Inc. (EDIT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| PACB | EDIT | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.13 | 1.16 | -1.03 |
Sortino ratioReturn per unit of downside risk | 0.96 | 2.16 | -1.20 |
Omega ratioGain probability vs. loss probability | 1.10 | 1.24 | -0.14 |
Calmar ratioReturn relative to maximum drawdown | 0.30 | 1.63 | -1.33 |
Martin ratioReturn relative to average drawdown | 0.63 | 3.10 | -2.47 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| PACB | EDIT | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.13 | 1.16 | -1.03 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.51 | -0.47 | -0.04 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | -0.21 | -0.28 | +0.07 |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.18 | -0.21 | +0.03 |
Correlation
The correlation between PACB and EDIT is 0.43, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Dividends
PACB vs. EDIT - Dividend Comparison
Neither PACB nor EDIT has paid dividends to shareholders.
Drawdowns
PACB vs. EDIT - Drawdown Comparison
The maximum PACB drawdown since its inception was -98.22%, roughly equal to the maximum EDIT drawdown of -98.92%. Use the drawdown chart below to compare losses from any high point for PACB and EDIT.
Loading graphics...
Drawdown Indicators
| PACB | EDIT | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.22% | -98.92% | +0.70% |
Max Drawdown (1Y)Largest decline over 1 year | -52.81% | -59.88% | +7.07% |
Max Drawdown (5Y)Largest decline over 5 years | -97.47% | -98.66% | +1.19% |
Max Drawdown (10Y)Largest decline over 10 years | -98.22% | -98.92% | +0.70% |
Current DrawdownCurrent decline from peak | -97.42% | -97.27% | -0.15% |
Average DrawdownAverage peak-to-trough decline | -70.20% | -61.98% | -8.22% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 24.93% | 31.49% | -6.56% |
Volatility
PACB vs. EDIT - Volatility Comparison
The current volatility for Pacific Biosciences of California, Inc. (PACB) is 19.48%, while Editas Medicine, Inc. (EDIT) has a volatility of 31.71%. This indicates that PACB experiences smaller price fluctuations and is considered to be less risky than EDIT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| PACB | EDIT | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 19.48% | 31.71% | -12.23% |
Volatility (6M)Calculated over the trailing 6-month period | 66.55% | 60.26% | +6.29% |
Volatility (1Y)Calculated over the trailing 1-year period | 91.97% | 98.42% | -6.45% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 93.91% | 93.19% | +0.72% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 84.47% | 83.41% | +1.06% |
Financials
PACB vs. EDIT - Financials Comparison
This section allows you to compare key financial metrics between Pacific Biosciences of California, Inc. and Editas Medicine, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities